. Author manuscript; available in PMC: 2021 Apr 27.

Published in final edited form as: Int J Cardiol. 2019 Mar 22;290:119–124. doi: 10.1016/j.ijcard.2019.03.040

Table 1.

Baseline characteristics of 50,932 participants with heart failure with preserved ejection fraction from 2002 to 2012

	HFpEF cohort (n=50,932)
Age (years)	72.2 (11.3)

Men (%)	96.4

*Race (%)*
White	84.6
Black	13.7
Other	1.7

*Body mass index (kg/m²) (%)*
Underweight (< 18.5)	4.6
Normal (18.5–24.9)	16.9
Overweight (25.0–29.9)	26.4
Obese (30.0–34.9)	22.6
Morbidly obese (≥ 35.0)	29.5

*Co-morbid conditions (%)*
Hypertension	89.6
Hyperlipidemia	66.5
Coronary artery disease	46.5
Atrial fibrillation	26.5
Diabetes Mellitus	55.7
COPD	48.4
Anemia	37.8

*Laboratory tests*
eGFR (mL/min/1.73 m²)	60.6 (24.7)
Serum Potassium (mEq/L)	4.22 (0.5)

*Medications (%)*
ACE/ARB	67.6
Beta Blocker	65.7
Calcium Channel Blocker	44.6

Column percentages are shown. Continuous variables are represented as mean ± standard deviation. Categorical variables are represented as frequency and percentage. Missing values are as follows: eGFR = 780, serum potassium=40, race=2,883. COPD = chronic obstructive pulmonary disease; ACE=Angiotensin-converting enzyme; ARB=Angiotensin receptor blocker; eGFR = estimated glomerular filtration rate. eGFR (estimated glomerular filtration rate) was estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.